Sergio Amadori

Summary

Affiliation: Catholic University
Country: Italy

Publications

  1. ncbi request reprint Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Ita
    S Amadori
    Department of Hematology, University Tor Vergata, Rome, Italy
    Leukemia 19:1768-73. 2005
  2. ncbi request reprint Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups
    Sergio Amadori
    Department of Hematology, University Tor Vergata, St Eugenio Hospital, Rome, Italy
    Haematologica 89:950-6. 2004
  3. pmc Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study
    Sergio Amadori
    Department of Hematology, University Tor Vergata, St Eugenio Hospital, P le dell Umanesimo, 10, 00144 Rome, Italy
    Blood 106:27-34. 2005
  4. ncbi request reprint Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow
    Luca Maurillo
    Dept of Hematology, Policlinico Tor Vergata and Ospedale S Eugenio, Rome, Italy
    Haematologica 92:605-11. 2007
  5. doi request reprint Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia
    Luca Maurillo
    Hematology, Policlinico Tor Vergata and Ospedale S Eugenio, Rome, Italy
    J Clin Oncol 26:4944-51. 2008
  6. pmc Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10
    Franco Mandelli
    Department of Cellular Biotechnologies and Hematology, SapienzaUniversity, Rome, Italy
    J Clin Oncol 27:5397-403. 2009
  7. ncbi request reprint Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia
    Giovanni Del Poeta
    Department of Hematology, University Tor Vergata, S Eugenio Hospital, Rome, Italy
    Cancer 112:119-28. 2008
  8. ncbi request reprint Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia
    Adriano Venditti
    Cattedra di Ematologia, Universita di Roma Tor Vergata, Divisione di Ematologia, Osp S Eugenio, P le dell Umanesimo 10, 00144 Rome, Italy
    Haematologica 89:934-9. 2004
  9. ncbi request reprint Mucositis in patients with hematologic malignancies: an overview
    Pasquale Niscola
    Haematology Division, Sant Eugenio Hospital and University Tor Vergata, Rome, Italy
    Haematologica 92:222-31. 2007
  10. doi request reprint Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia
    Giovanni Del Poeta
    Department of Hematology, University Tor Vergata, Roma, Italy
    Leuk Lymphoma 51:95-106. 2010

Detail Information

Publications57

  1. ncbi request reprint Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Ita
    S Amadori
    Department of Hematology, University Tor Vergata, Rome, Italy
    Leukemia 19:1768-73. 2005
    ..05). We conclude that the dose/schedule of gemtuzumab ozogamicin used in this trial is too toxic in the age group over 75 years. For these patients, additional studies with reduced doses of the immunotoxin are warranted...
  2. ncbi request reprint Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups
    Sergio Amadori
    Department of Hematology, University Tor Vergata, St Eugenio Hospital, Rome, Italy
    Haematologica 89:950-6. 2004
    ..The aim of this collaborative trial was to assess the feasibility, safety, and antileukemic activity of administering GO followed by conventional chemotherapy as first line therapy in patients aged 61-75 years with AML...
  3. pmc Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study
    Sergio Amadori
    Department of Hematology, University Tor Vergata, St Eugenio Hospital, P le dell Umanesimo, 10, 00144 Rome, Italy
    Blood 106:27-34. 2005
    ..2 vs 29.7 days; P < .001). We conclude that although priming with G-CSF can improve the CR rate, the use of G-CSF during and/or after chemotherapy has no effect on the long-term outcome of AML in older patients...
  4. ncbi request reprint Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow
    Luca Maurillo
    Dept of Hematology, Policlinico Tor Vergata and Ospedale S Eugenio, Rome, Italy
    Haematologica 92:605-11. 2007
    ..In the present study, we investigated whether peripheral blood (PB) could be an alternative source of cells for monitoring MRD in AML...
  5. doi request reprint Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia
    Luca Maurillo
    Hematology, Policlinico Tor Vergata and Ospedale S Eugenio, Rome, Italy
    J Clin Oncol 26:4944-51. 2008
    ..The effects of autologous (AuSCT) or allogeneic stem-cell transplantation (SCT) are still under evaluation. Minimal residual disease (MRD) states may be essential for assigning patients to therapy-dependent risk categories...
  6. pmc Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10
    Franco Mandelli
    Department of Cellular Biotechnologies and Hematology, SapienzaUniversity, Rome, Italy
    J Clin Oncol 27:5397-403. 2009
    ..To compare the antitumor efficacy of three different anthracyclines in combination with cytarabine and etoposide in adult patients with newly diagnosed acute myeloid leukemia (AML)...
  7. ncbi request reprint Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia
    Giovanni Del Poeta
    Department of Hematology, University Tor Vergata, S Eugenio Hospital, Rome, Italy
    Cancer 112:119-28. 2008
    ....
  8. ncbi request reprint Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia
    Adriano Venditti
    Cattedra di Ematologia, Universita di Roma Tor Vergata, Divisione di Ematologia, Osp S Eugenio, P le dell Umanesimo 10, 00144 Rome, Italy
    Haematologica 89:934-9. 2004
    ..The objective of this study was to investigate the expression of MDR1 and bcl-2 proteins in de novo acute myeloid leukemia (AML)...
  9. ncbi request reprint Mucositis in patients with hematologic malignancies: an overview
    Pasquale Niscola
    Haematology Division, Sant Eugenio Hospital and University Tor Vergata, Rome, Italy
    Haematologica 92:222-31. 2007
    ..Nevertheless, in the last decade, a better insight into the pathogenesis of the mucosal damage has led to the development of novel therapeutic options which potentially could allow a targeted approach to mucositis...
  10. doi request reprint Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia
    Giovanni Del Poeta
    Department of Hematology, University Tor Vergata, Roma, Italy
    Leuk Lymphoma 51:95-106. 2010
    ..03) was confirmed within ZAP-70 negative patients. Bcl-2 and CD71 can be considered as interesting progression indicators, which should be validated in an independent cohort of patients, to take timely therapeutic decisions in CLL...
  11. doi request reprint The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia
    Giovanni Del Poeta
    Department of Haematology, Ospedale S Eugenio, University Tor Vergata, Rome, Italy
    Br J Haematol 149:383-7. 2010
    ..35 subset showed a very high CR rate (96%), very long OS (P = 0.00005) and disease-free survival (P = 0.004). The favourable prognosis of NPM1-mt/FLT3-ITD negative patients might be explained by a higher bax/bcl-2 ratio...
  12. doi request reprint Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia
    Francesco Buccisano
    Hematology, Fondazione Policlinico Tor Vergata, Viale Oxford 81, Rome, Italy
    Blood 116:2295-303. 2010
    ..001 for all comparisons). In AML, the integrated evaluation of baseline prognosticators and MRD improves risk-assessment and optimizes postremission therapy...
  13. doi request reprint Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group
    Francesco Lo-Coco
    Department of Biopathology, University Tor Vergata of Rome, Via Montpellier 1, Rome, Italy
    Blood 116:3171-9. 2010
    ..Furthermore, our results highlight the role of cytarabine coupled to anthracyclines and ATRA during consolidation in the high-risk group...
  14. doi request reprint Monitoring of minimal residual disease in acute myeloid leukemia
    Francesco Buccisano
    Department of Biopatologia e Diagnostica per Immagini, Fondazione Policlinico Tor Vergata and Ospedale S Eugenio, Rome, Italy
    Curr Opin Oncol 21:582-8. 2009
    ..In the present review we will focus on the use of MPFC for monitoring of MRD, addressing the main technical and clinical issues...
  15. doi request reprint Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation
    Tiziana Ottone
    Dipartimento di Biopatologia e Diagnostica per Immagini, University Tor Vergata, Rome, Italy
    Genes Chromosomes Cancer 48:213-21. 2009
    ..This study suggests a wider distribution in the human genome, and particularly at genes involved in chromosome translocations observed in t-AML, of DNA regions (hotspot) targeted by specific topo II drugs...
  16. ncbi request reprint Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia
    Maria Ilaria Del Principe
    Department of Hematology, Universita Tor Vergata, Ospedale S Eugenio, Rome, Italy
    Haematologica 89:1468-75. 2004
    ..This study tests the hypothesis that soluble p53 alone and in association with CD38 can enucleate B-CLL subsets at worse prognosis...
  17. ncbi request reprint Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia
    Maria Ilaria Del Principe
    Cattedra di Ematologia, Universita Tor Vergata, Ospedale S Eugenio, Via Fiume Giallo, 430 MA, 00144 Roma, Rome, Italy
    Blood 108:853-61. 2006
    ..On this line, we recommend and are also interested in conducting a prospective randomized trial of early intervention versus observation for ZAP-70(+) patients...
  18. pmc CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study
    Giovanni Del Poeta
    Department of Hematology, University Tor Vergata, Roma
    Haematologica 97:279-87. 2012
    ..Chronic lymphocytic leukemia is a clinically heterogeneous disease which needs novel prognostic parameters which can be easily and efficiently managed...
  19. ncbi request reprint Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia
    Adriano Venditti
    Cattedra di Ematologia, Universita di Roma Tor Vergata, Divisione di Ematologia, Osp S Eugenio, P le dell Umanesimo 10 00144, Rome, Italy
    Leuk Lymphoma 44:445-50. 2003
    ..This review will focus on the state of art of MRD detection in acute myeloid leukemia (AML) using multidimensional flow cytometry (MFC), and will cover the laboratory and clinical aspects of this approach...
  20. ncbi request reprint Comparison between conventional banding analysis and FISH screening with an AML-specific set of probes in 260 patients
    Maria Christina Cox
    Department of Hematology, University Tor Vergata, St Eugenio Hospital, Rome, Italy
    Hematol J 4:263-70. 2003
    ..Furthermore, we suggest FISH screening in failed, complex or suboptimal quality chromosome and specific FISH analysis for 5q, 7q, 12p, 17p, inv(16), t(11q23) in order to implement CBA accuracy...
  21. doi request reprint Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin
    Tiziana Ottone
    Department of Biopathology, University of Tor Vergata, Rome, Italy
    Br J Haematol 161:533-40. 2013
    ..Our data underscore the need of identifying low FLT3 ITD levels, which are probably associated with relapse in otherwise good prognosis CN-AML...
  22. doi request reprint Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA loci
    Syed Khizer Hasan
    Department of Biopathology, University of Rome Tor Vergata, Rome, Italy
    Genes Chromosomes Cancer 49:726-32. 2010
    ..Biased distribution of DNA breakpoints at both PML and RARA loci suggest the existence of different pathogenetic mechanisms in t-APL as compared with de novo APL...
  23. pmc An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia
    Tiziana Ottone
    Dipartimento di Biopatologia e Diagnostica per Immagini, University Tor Vergata, Rome, Italy
    J Mol Diagn 10:212-6. 2008
    ..This method is convenient and easily applicable in countries with limited resources and no access to real-time quantitative PCR-based technologies...
  24. pmc Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leuka
    Sergio Amadori
    Tor Vergata University Hospital, Rome, Italy
    Br J Haematol 149:376-82. 2010
    ..The day 1 + 8 schedule, which was associated with the highest rate of DnP, met the statistical criteria to be selected as the preferred regimen for phase III comparison with best supportive care...
  25. doi request reprint Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
    Francesco Lo-Coco
    Dipartimento di Biomedicina e Prevenzione, Universita Tor Vergata, Rome, Italy
    N Engl J Med 369:111-21. 2013
    ..Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity...
  26. ncbi request reprint Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes
    Francesco Buccisano
    Department of Biopatologia e Diagnostica per Immagini, Policlinico Tor Vergata and Ospedale S Eugenio, Rome, Italy
    Eur J Haematol 80:107-14. 2008
    ..An aberrant pattern of expression of L-selectin and intercellular adhesion molecule 1 (ICAM1) may characterise CD34+ blast cells in myelodysplastic syndromes (MDS) and secondary acute myeloid leukaemia (sAML)...
  27. ncbi request reprint Recombinant factor VIIa for the management of severe hemorrhages in patients with hematologic malignancies
    Paolo De Fabritiis
    Hematology, University Tor Vergata, St Eugenio Hospital, Rome, Italy
    Haematologica 89:243-5. 2004
  28. ncbi request reprint Home care management of patients affected by hematologic malignancies: a review
    Pasquale Niscola
    Haematology Division, Tor Vergata University, Sant Eugenio Hospital, Via dell Umanesimo 10, 00144 Rome, Italy
    Haematologica 91:1523-9. 2006
    ..Therefore, all efforts should be made to overcome budget and administrative barriers and to ensure a more widespread use of this model of care...
  29. ncbi request reprint P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia
    Maria Ilaria Del Principe
    Department of Haematology, University Tor Vergata, St Eugenio Hospital, Roma, Italy
    Br J Haematol 121:730-8. 2003
    ..Therefore, in adult ALL, PGP and bcl-2 represent sensitive indicators of clinical outcome, and potential targets of novel molecules aimed at overcoming chemoresistance and recurrent relapses...
  30. ncbi request reprint Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation
    Emanuele Ammatuna
    Dipartimento di Biopatologia e Diagnostica per Immagini, University Tor Vergata via Montpellier, Rome, Italy
    Ann Hematol 86:355-61. 2007
    ..We conclude that this non-isotopic and rapid assay amenable to automation may be adopted in routine genetic diagnosis of CMDs as well as for initial screening of thrombocytosis of unknown nature...
  31. doi request reprint Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia
    Francesco Buccisano
    Hematology, Fondazione Policlinico Tor Vergata, Rome, Italy
    Blood 119:332-41. 2012
    ..A comprehensive prognostic algorithm, generated by combining pretreatment cytogenetics/genetics and posttreatment MRD determination, should promote advances in development of personalized therapeutic approaches...
  32. doi request reprint Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells
    Gabriella Marfe
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy
    Exp Hematol 39:653-665.e6. 2011
    ..Therefore, it is of great importance to understand the molecular mechanisms affecting cancer cell sensitivity and resistance to tyrosine kinase inhibitors...
  33. ncbi request reprint Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients
    M Christina Cox
    Department of Hematology, S Eugenio Hospital, University of Tor Vergata, Rome, Italy
    Am J Clin Pathol 122:298-306. 2004
    ..Moreover, these cases should be readily distinguishable from 11q23+/MLL+ cases. We recommend that karyotypic analysis always be complemented by molecular or FISH methods to unravel MLL rearrangements...
  34. doi request reprint Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) exert their anti-proliferative activity by interfering with Akt-mTOR signaling and bax:bcl-2 ratio modulation in cells from chronic myeloid leukemic patients
    Carla Di Stefano
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy
    Cancer Sci 101:991-1000. 2010
    ..These compounds constitute a promising therapeutic approach for patients with leukemia. They provide the basis for new strategies for an additional anticancer drug in leukemia therapies, especially when conventional ones fail...
  35. pmc A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation
    Giuseppe Gentile
    Department of Cellular Biotechnology and Hematology, Univ, La Sapienza, Rome, Italy
    BMC Infect Dis 6:167. 2006
    ..Quantitative CMV-DNA PCR assay in plasma has been proposed to monitor CMV infection in SCT patients. We evaluated the clinical utility of pp65Ag and PCR assay in plasma of SCT recipients...
  36. doi request reprint Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia
    Roberto Latagliata
    Ematologia, Universita La Sapienza, Rome, Italy
    Br J Haematol 143:681-9. 2008
    ..DNX seems to improve OS and DFS in the long-term follow-up, because of a reduction in late relapses...
  37. pmc Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy
    Chiara Sarlo
    Department of Hematology, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
    Leuk Res Treatment 2013:705714. 2013
    ..Clinical registration no.: EUDRACT 2006-006923-38...
  38. ncbi request reprint Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation
    Alessandra Picardi
    Hematology, University Tor Vergata, St Eugenio Hospital, Rome, Italy
    Hematol J 5:24-31. 2004
    ..provide durable responses in patients not eligible for conventional SCT exploiting the graft-versus-malignancy effect and (3). is loaded by an high rate of fatal infections...
  39. ncbi request reprint Monoclonal antibodies and immunoconjugates in acute myeloid leukemia
    Sergio Amadori
    Department of Hematology, Tor Vergata University Hospital, Viale Oxford 81, 00133 Rome, Italy
    Best Pract Res Clin Haematol 19:715-36. 2006
    ..Whether or not monoclonal antibody therapy will improve disease outcome compared with conventional treatment regimens remains to be demonstrated by well-designed clinical trials...
  40. ncbi request reprint Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies
    Tommaso Caravita
    Myeloma Unit, Hematology Department, St Eugenio Hospital, Rome, Italy
    Nat Clin Pract Oncol 3:374-87. 2006
    ..This article summarizes the principal clinical trials of bortezomib and discusses its efficacy in solid and hematologic tumors...
  41. doi request reprint Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab
    Roberto Stasi
    Department of Medical Sciences, Ospedale Regina Apostolorum, Albano Laziale, Rome, Italy
    Blood 112:1147-50. 2008
    ..These results indicate that patients with active ITP have a defective T regulatory cell compartment that can be modulated by a B cell-targeted therapy...
  42. doi request reprint Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes
    Maria Teresa Voso
    Istituto di Ematologia, Universita Cattolica S Cuore, Rome, Italy
    Clin Cancer Res 15:5002-7. 2009
    ..We conducted a phase II multicenter study on the combination of the DNA-methyltransferase inhibitor 5-azacytidine (5-AZA) and the histone deacetylase inhibitor valproic acid (VPA) in patients with higher risk MDS...
  43. doi request reprint Molecular characterization of paediatric idiopathic hypereosinophilia
    Maria Cristina Rapanotti
    Department of Laboratory Medicine, Policlinico Tor Vergata, Rome, Italy
    Br J Haematol 151:440-6. 2010
    ..IGH rearrangement was observed to be a frequent molecular feature of pHES and may precede B-cell clonal expansion and evolution into B-cell malignancies in children...
  44. ncbi request reprint Opioids in pain management of blood-related malignancies
    Pasquale Niscola
    Hematology Division, Sant Eugenio Hospital, Tor Vergata University, Via dell Umanesimo 10, 00144, Rome, Italy
    Ann Hematol 85:489-501. 2006
    ..This article reviews the principles of opioid therapy and how opioids can be adapted for patients with pain due to haematological malignancies...
  45. doi request reprint Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia
    Francesco Lo-Coco
    Department of Biopathology, University Tor Vergata, Via Montpellier 1, 00161 Rome, Italy
    Haematologica 93:1017-24. 2008
    ..The aim of this study was to verify this prospectively in a large group of patients...
  46. ncbi request reprint Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia
    Giuseppe Cimino
    Department of Cellular Biotechnology and Hematology, University of Rome La Sapienza, Rome, Italy
    Cancer Res 66:8903-11. 2006
    ..Further studies are needed to evaluate whether VPA-ATRA treatment by reprogramming differentiation of the leukemic clone might improve the response to chemotherapy in leukemia patients...
  47. ncbi request reprint Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors
    Antonio Bruno
    Department of Immunohematology, University Tor Vergata, Bambino Gesu Hospital, Rome, Italy
    Transfus Apher Sci 26:103-10. 2002
    ..Positive selection of CD34+ cells seems to be related to the quality of the apheresis products, particularly to the initial CD34+ cell and PLT content...
  48. ncbi request reprint Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study
    Luciana Annino
    Department of Cellular Biotechnology and Hematology, Universita degli Studi La Sapienza, via Benevento, 6 00161, Rome, Italy
    Blood 99:863-71. 2002
    ..Neither induction intensification nor early consolidation appeared to influence CCR and DFS duration. For the first time PDN pretreatment response proved to be a powerful factor predicting disease outcome in adult ALL patients...
  49. pmc Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis
    Syed Khizer Hasan
    Department of Biopathology, University of Tor Vergata, Rome, Italy
    Blood 112:3383-90. 2008
    ..This study further supports the presence of preferential sites of DNA damage induced by mitoxantrone in PML and RARA genes that may underlie the propensity to develop this subtype of leukemia after exposure to this agent...
  50. doi request reprint Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia
    Sergio Amadori
    Department of Hematology, Tor Vergata University Hospital, Rome, Italy
    Curr Opin Hematol 15:95-100. 2008
    ..This review addresses use of monoclonal antibodies and immunoconjugates to treat acute myeloid leukemia...
  51. ncbi request reprint Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC
    Emanuele Ammatuna
    Dipartimento di Biopatologia e Diagnostica per Immagini, University Tor Vergata, Rome, Italy
    Clin Chem 51:2165-7. 2005
  52. pmc PYRROLO[1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) induce apoptosis in K562 cells
    Gabriella Marfe
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy
    BMC Cancer 7:207. 2007
    ..The objective of this study was to gain insight into the molecular mechanism of induced cell death (apoptosis) by PYRROLO [1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) series compounds, using human (K562) cells as a model...
  53. ncbi request reprint Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia
    Adriano Venditti
    Cattedra di Ematologia, Universita di Roma Tor Vergata, Divisione di Ematologia, Osp S Eugenio, P le dell Umanesimo 10 00144, Rome, Italy
    J Hematother Stem Cell Res 11:349-57. 2002
    ..Thus, a MRD > or = 3.5 x 10(-4) leukemic cells at the end of consolidation strongly predicts relapse, and is significantly associated with MDR1-positive phenotype and intermediate/unfavorable cytogenetics...
  54. pmc Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia
    Roberto Stasi
    Department of Medical Sciences, Ospedale Regina Apostolorum, Albano Laziale, Rome, Italy
    PLoS Med 3:e24. 2006
    ..The long-term outcome of individuals with mild degrees of thrombocytopenia is unknown...
  55. ncbi request reprint Survival of elderly patients with acute myeloid leukemia
    Alessandro Pulsoni
    Dpt of Cellular Biotechnology and Hematology, La Sapienza University, Roma, Italy
    Haematologica 89:296-302. 2004
    ..We retrospectively evaluated the impact on survival of an aggressive versus a non-aggressive approach in 1005 patients aged >60 years registered in the database of the GIMEMA cooperative group...
  56. ncbi request reprint Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells
    Paolo Corradini
    Division of Hematology Bone Marrow Transplantation, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian, 1, 20133 Milano, Italy
    J Clin Oncol 22:2172-6. 2004
    ..We performed a pilot study to investigate the role of reduced-intensity conditioning (RIC) followed by allogeneic stem-cell transplantation in relapsed or refractory PTCLs...
  57. ncbi request reprint Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages
    Federico Pea
    Department of Experimental and Clinical Pathology and Medicine, Medical School, Institute of Clinical Pharmacology and Toxicology, University of Udine, Udine, Italy
    Clin Pharmacokinet 43:405-15. 2004
    ....